Update on gout: Pathophysiology and potential treatments

Current Pain and Headache Reports

Volumn 11, Issue 6, 2007, Pages 440-446

  Abeles, Aryeh M ^a   Park, Jean Y ^b   Pillinger, Michael H ^b   Cronstein, Bruce N ^b  

^a Division of Rheumatology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; COLCHICINE; CORTICOTROPIN; FEBUXOSTAT; GLUCOCORTICOID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGURICASE; PROBENECID; PROSTAGLANDIN SYNTHASE INHIBITOR; RASBURICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; SULFINPYRAZONE; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; URICOSURIC AGENT;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE KIDNEY FUNCTION RELATION; DRUG CROSS REACTIVITY; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; KIDNEY FAILURE; LIVER FAILURE; NEUROMUSCULAR DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIMATE; REVIEW; STEVENS JOHNSON SYNDROME; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERTENSION; HYPERURICEMIA; IMMUNITY, NATURAL; INFLAMMATION; PRIMATES; URIC ACID;

EID: 36949008161     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-007-0231-3     Document Type: Review

References (58)

1. Nuki G, Simkin PA: A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006, 8(Suppl 1):S1.
2. Terkeltaub RA, Ginsberg MH: The inflammatory reaction to crystals. Rheum Dis Clin North Am 1988, 14:353-364.
3. Terkeltaub R: Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis 2006, 64:82-86.
4. Schumacher HR Jr: Pathology of crystal deposition diseases. Rheum Dis Clin North Am 1988, 14:269-288.
5. Schumacher HR Jr: Crystal deposition disease. Curr Opin Rheumatol 1997, 9:251-252.
6. Ogura Y, Sutterwala FS, Flavell RA: The inflammasome: first line of the immune response to cell stress. Cell 2006, 126:659-662.
7. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
8. Jin Y, Mailioux CM, Gowan K, et al.: NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007, 356:1216-1225.
9. Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
10. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and mycloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
11. Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271.
12. Liu R, O'Connell M, Johnson K, et al.: Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000, 43:1145-1155.
13. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
14. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
15. Gallucci S, Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
16. Skoberne M, Beignon AS, Bhardwaj N: Danger signals: a time and space continuum. Trends Mol Med 2004, 10:251-257.
17. Andrews NW: Membrane repair and immunological danger. EMBO Rep 2005, 6:826-830.
18. Hu DE, Moore AM, Thomsen LL, Brindle KM: Uric acid promotes tumor immune rejection. Cancer Res 2004, 64:5059-5062.
19. Wu XW, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992, 34:78-84.
20. Watanabe S, Kang DH, Feng L, et al.: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002, 40:355-360.
21. Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
22. Feig DI, Nakagawa T, Karumanchi SA, et al.: Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004, 66:281-287.
23. Feig DI, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ: Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension. Hypertension 2006, 48:25-26,
24. Kanellis J, Watanabe S, Li JH, et al.: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
25. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al.: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002, 283:F1105-F1110.
26. Feig DI, Johnson RJ: The role of uric acid in pediatric hypertension. J Ren Nutr 2007, 17:79-83.
27. Puig JG, Ruilope LM: Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999, 17:869-872.
28. Lee J, Sparrow D, Vokonas PS, et al.: Uric acid and coronary heart disease risk- evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995, 142:288-294.
29. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7-13.
30. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:.2404-2410.
31. Niskanen LK, Laaksonen DE, Nyyssonen K, et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-1551.
32. Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
33. Alderman M, Aiyer KJ: Uric acid: rote in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004, 20:369-379.
34. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988, 224:549-555.
35. Levine W, Dyer AR, Shekelle RB, et al.: Serum uric acid an 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989, 42:257-267.
36. Wang JG, Staessen JA, Fagard RH, et al.: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001, 37:1069-1074.
37. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic hear disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141:637-644.
38. Franse LV, Pahor M, Di Bari M, et al.: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000, 18:1149-1154.
39. Reunanen A, Takkunen H, Knekt P, Aromaa A: Hyperurice mia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl 1982, 668:49-59.
40. Arromdee E, Michet CJ, Crowson CS, et al.: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403-2406.
41. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004, 31:1582-1587.
42. Choi HK, Atkinson K, Karlson EW, et al.: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093-1103.
43. Choi HK, Liu S, Curhan G: Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 52:283-289.
44. Choi HK, Atkinson K, Karlson EW, er al.: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004, 363:1277-1281.
45. Terkeltaub R, Bushinsky DA, Becker MA: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006, 8(Suppl 1):S4.
46. Enomoto A, Kimura H, Chairoungdua A, et al.: Molecular identification of a renal orate anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.
47. Hatch M, Freel RW, Shahinfar S, Vaziri ND: Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther 1996, 276:187-193.
48. Lipkowitz MS, Leal-Pinto E, Rappoport JZ, et al.: Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001, 107:1103-1115.
49. Malawista SE, Bensch KG: Human polymorphonuclear leukocytes: demonstration of microtubules and effect of colchicine. Science 1967, 156:521-522.
50. Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994-1002.
51. Abramson SB: Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1992, 4:295-300.
52. Terkeltaub RA: Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.
53. Becker MA, Schumacher FIR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol. in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
54. Schumacher HR Jr: Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005, 14:893-903.
55. Rampello E, Fricia T, Malaguamera M: The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006, 3:438-447.
56. Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006, 2:338-342; quiz 343.
57. Sundy JS, Ganson NJ, Kelly SJ, et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028.
58. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.